Department of Obstetrics Gynecology and Reproductive Medicine, Dexeus Mujer, Dexeus University Hospital Barcelona, Spain.
Gynecology and Obstetrics 1U, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, Sant'Anna Hospital, University of Turin, Turin, Italy.
Reprod Biomed Online. 2022 Jun;44(6):1015-1022. doi: 10.1016/j.rbmo.2022.02.003. Epub 2022 Feb 12.
Does type of LH peak suppression (progesterone-primed ovarian stimulation [PPOS] versus gonadotrophin releasing hormone [GnRH] antagonist) affect oocyte competence, embryo development and live birth rates in recipients of vitrified donated oocytes?
Retrospective cohort study conducted between 2016 and 2018, involving 187 recipient cycles of donated vitrified oocytes. Oocyte donors were stimulated under LH suppression with desogestrel for PPOS (DSG group) or ganirelix GnRH antagonist (ANT group). Recipients younger than 50 years received vitrified oocytes from DSG donation cycles (DSG-R) or ANT donation cycles (ANT-R).
A mean of 10.07 ± 3.54 oocytes per recipient were warmed (survival rate of 80.7%), and 5.90 ± 2.89 were fertilized (fertilization rate 72.6%). Out of 187 recipients, 168 achieved embryo transfers. No significant differences were found in warming survival rates, fertilization rates and embryo development between DSG-R and ANT-R groups. Ninety-four clinical pregnancies and 81 live births were achieved. No statistically significant differences were found in clinical pregnancy rates (47.7% versus 52.5, P = 0.513) and live birth rates (39.5% versus 46.5%, P = 0.336) per recipient cycle between DSG-R and ANT-R, respectively. Multivariable logistic regression was applied to assess the effect of treating oocyte donors. Live birth rate adjusted for associated factors was not statistically different between vitrified oocytes from DSG or ANT (OR 0.74, 95% CI 0.37 to 1.47).
Reproductive outcomes of recipients of vitrified oocytes are not affected by donor PPOS treatment. PPOS is suitable for suppressing LH peak in elective fertility preservation and in freeze-all strategies.
黄体生成素抑制类型（孕激素预处理的卵巢刺激[PPOS]与促性腺激素释放激素[GnRH]拮抗剂）是否会影响接受玻璃化捐赠卵母细胞的患者的卵母细胞能力、胚胎发育和活产率？
这是一项回顾性队列研究，于 2016 年至 2018 年进行，涉及 187 个接受玻璃化捐赠卵母细胞的受者周期。卵母细胞供体通过地屈孕酮（PPOS 组）或加尼瑞克 GnRH 拮抗剂（ANT 组）抑制 LH 进行刺激。年龄小于 50 岁的受者接受来自 DSG 捐赠周期（DSG-R）或 ANT 捐赠周期（ANT-R）的玻璃化捐赠卵母细胞。
每个受者平均解冻 10.07±3.54 个卵母细胞（存活率为 80.7%），解冻后有 5.90±2.89 个卵母细胞受精（受精率为 72.6%）。在 187 名受者中，有 168 名进行了胚胎移植。DSG-R 组和 ANT-R 组在解冻存活率、受精率和胚胎发育方面无显著差异。获得 94 例临床妊娠和 81 例活产。DSG-R 组和 ANT-R 组的临床妊娠率（分别为 47.7%和 52.5%，P=0.513）和活产率（分别为 39.5%和 46.5%，P=0.336）无统计学差异。应用多变量逻辑回归评估治疗卵母细胞供体的效果。在调整了相关因素后，玻璃化的来自 DSG 或 ANT 的卵母细胞的活产率无统计学差异（OR 0.74，95%CI 0.37 至 1.47）。
接受玻璃化卵母细胞的受者的生殖结局不受供体 PPOS 治疗的影响。PPOS 适用于选择性生育力保存和冷冻全部策略中抑制 LH 峰。
